China channel feed – Endpoints News

China channel feed

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

8 years ago

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

8 years ago

Top 5 biopharma trends: The long-awaited biopharma revolution in China has arrived — don’t lose out

8 years ago

As China biotech booms, Fidelity group rolls out $250M fund with a big focus on drug R&D

8 years ago

Celgene-partnered Antengene preps new China deals as $21M round lands

8 years ago

With a big stake in hand, Samantha Du files for $115M IPO for Zai Lab

8 years ago

China biotech bags a $57M round as it races to complete R&D, manufacturing site

8 years ago

10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul

8 years ago

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

9 years ago

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

9 years ago

New Chinese VC leads $10M round for a Harvard spinout looking to industrialize platelet manufacturing

9 years ago

Nanjing Legend wows ASCO researchers with early data on a BCMA-targeted CAR-T contender

9 years ago

China biotech startup InventisBio bags a $19M round for early-stage R&D

9 years ago

Ge Li melds WuXi VC with Frontline, creating an $800M trans-Pacific powerhouse fund now hunting fresh biotech capital

9 years ago

Ge Li’s fast-growing WuXi Biologics sets the stage for a $513M IPO

9 years ago

Zai Lab CEO Samantha Du is raising a $150M biotech fund

9 years ago

China has a $1.45B plan to build up its biotech hubs — and officials are moving fast

9 years ago

Shanghai-based EpimAb Bio grows global roots with $25M A round and a key assist by Robert Kamen

9 years ago

With a big cash assist from local officials, BeiGene is building a $330M biologics facility in China

9 years ago

FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies

9 years ago

Innovent Biologics sets a biotech record in China with $260M raise for PhIII work

9 years ago

China backers help bankroll a $100M mega-round as an influential antibody engineer readies trials

9 years ago

First page Previous page 26 27 282930 Next page Last page